Unresectable Metastatic Right-sided Colon Cancer Starting First-line Combination Chemotherapy Clinical Trial
Official title:
A Randomized, Open-label, Multicenter Phase II Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan/Oxaliplatin (A-FOLFIRI/FOLFOX) as First-line Treatment for Metastatic Right-sided Colon Cancer
| Verified date | October 2020 |
| Source | Yonsei University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
RATIONALE: Recently, the importance of prognosis according to the location of the primary tumor in colorectal cancer has been raised. In the CALGB / SWOG 80405 study published in 2016, the addition of bevacizumab or cetuximab to the first line FOLFIRI / FOLFOX in KRAS (codon 12, 13) wild type metastatic colorectal cancer (mCRC) patients did not show a significant difference between overall survival (OS) and progression free survival (PFS) in both groups. Alan P. Venook et al. published a follow-up subgroup analysis on the effect of primary tumor location at 2016 ASCO. In the treatment group with cetuximab, the difference in treatment effect was significant according to the primary tumor location. The right colon cancer showed a poor prognosis for cetuximab treatment. (PFS: 7.8 vs 12.4 months, HR 1.56, p <0.0001 / OS: 16.7 vs 36.0months, HR 1.87, P <0.0001). Therefore, the investigators propose a phase II trial for the efficacy evaluation of bevacizumab-FOLFOXIRI and bevacizumab-FOLFIRI or FOLFOX treatment in patients with poor prognosis of unresectable right-sided colorectal cancer.
| Status | Recruiting |
| Enrollment | 120 |
| Est. completion date | June 2024 |
| Est. primary completion date | June 2024 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 19 Years and older |
| Eligibility | Inclusion Criteria: - Histologically proven diagnosis of unresectable recurrent or advanced stage IV right-sided colon cancer (The definition of the right colon cancer is confirmed by the colonoscopy result, the surgical report, or the image reading paper including CT, MRI, and PET CT. (cecum~splenic flexure)) - Not previously treated with chemotherapy for metastatic disease - At least one measurable lesion according to RECIST criteria - Age over 19 years old - ECOG 0~2 - Life expectancy of at least 3 months - Adequate major organ functions - ANC = 1.5 x 109/L - PLT = 100 x 109/L - Hb = 9.0 g/dL (can be corrected by blood transfusion) - Total bilirubin = upper normal limit(UNL) * 1.5 - ALT , AST = UNL * 3 (in case of liver metastasis, ALT , AST = UNL * 5), alkaline phosphatase = UNL *3 (in case of liver metastasis, ALP = UNL * 5 - adequate renal function : corrected creatinine clearance by Cockcroft and Gault formula = 30mL/min - Urine dipstick of proteinuria <2+. Patients discovered to have 2+ proteinuria on dipstick urinalysis at baseline, should undergo a 24-hour urine collection and must demonstrate 1 g of protein/24 hr. - Written informed consent. Exclusion Criteria: - Previously treated with chemotherapy for metastatic disease - Within 6 months after adjuvant chemotherapy - Major surgical procedure within 28 days prior to study treatment start, or patients who have not fully recovered from major surgery - Radiotherapy to target lesion within 4 weeks before the study (A 2-week washout is permitted for palliative radiation.) - Has known uncontrolled active CNS metastases and/or carcinomatous meningitis - Peripheral neuropathy CTCAE v4.03 = grade 2 - Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of skin, squamous cell carcinoma of the skin, low grade thyroid cancer or carcinoma in situ (eg, cervical cancer in situ) that have undergone potentially curative therapy are not excluded. - Has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy, such as thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, is not considered a form of systemic systemic treatment and is allowed. - Uncontrolled hypertension or clinically active cardiovascular disease: for example, cerebrovascular accident or transient ischemic attack, unstable angina, myocardial infarction within 24 weeks prior to randomization. Have symptomatic congestive heart failure (CHF; New York Heart Association II-IV) or symptomatic or poorly controlled cardiac arrhythmia. - Have significant bleeding disorders, or evidence of bleeding diathesis or coagulopathy - Have had a significant bleeding episode from the gastrointestinal (GI) tract or lung - Have a history of GI perforation and/or fistula, or intra-abdominal abscess within 24 weeks prior to randomization. - Have a history of HNPCC syndrome or polyposis - Have experienced any arterial thromboembolic event or ongoing treatment with anticoagulants for therapeutic purpose within 24 weeks prior to randomization. - Has a known history of human immunodeficiency virus (HIV) infection - Are pregnant or breast feeding. Females of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to first dose of study treatment. For women of childbearing potential and men, agreement to remain abstinent or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 30 days after the last dose of study drugs. Postmenopausal women is defined that : 1) must have been amenorrheic for at least 12 months, > 50 years old or 2) Age = 50 years old and amenorrheic for 12 or more months in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression and follicle-stimulating hormone (FSH) and estradiol in the postmenopausal range (>40 mIU/mL), 3) prior bilateral oophorectomy - Patients who are hypersensitive reaction to experimental drugs - Patients who are hypersensitive to CHO cell products or other recombinant or humanized antibodies - In case of contraindication of experimental drugs - Have any condition (eg, psychological, geographical, or medical) that does not permit compliance with the study and follow-up procedures or suggest that the patient is, in the investigator's opinion, not an appropriate candidate for the study. |
| Country | Name | City | State |
|---|---|---|---|
| Korea, Republic of | Yonsei Cancer Center, Severance Hospital, Yonsei University Health System | Seoul |
| Lead Sponsor | Collaborator |
|---|---|
| Yonsei University |
Korea, Republic of,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | 6-month PFS rate (%) | To compare the 6-month progression free survival (PFS) rate (%) of bevacizumab in combination with oxaliplatin, irinotecan and infusional 5FU/LV (A-FOLFOXIRI regimen) to bevacizumab in combination with oxaliplatin or irinotecan and infusional 5FU/LV (A-FOLFOX/A-FOLFIRI regimen) in not previously treated, unresectable stage IV right-sided colon cancer | 6 months | |
| Secondary | overall survival(OS) | To compare the overall survival (OS) between treatment arms | 4 years | |
| Secondary | progression free survival(PFS) | To compare the progression free survival (PFS) between treatment arms | 4 years | |
| Secondary | adverse events | To evaluate the safety profile including long-term adverse events between treatment arms | 4 years | |
| Secondary | surrogate markers predictive of survival: ctDNA | To evaluate the correlation between 6-month PFS rate(%) and change in ctDNA | 4 years |